The clinical and bacteriological efficacy and the tolerability of meropenem versus imipenem/cilastatin (both 1 g t.i.d.) in severe nosocomial infections were compared in a multicentre, randomised, nonblinded study. A total of 151 patients were recruited; 133 (66 meropenem, 67 imipenem/cilastatin) were clinically evaluable and 84 (42 meropenem, 42 imipenem/cilastatin) bacteriologically evaluable. Most clinically evaluable patients (90%) were in intensive care units, required mechanical ventilation (72%), and had received previous antibiotic therapy (62%). The mean (+/- SD) APACHE II score was 15.2 (+/- 6.6) in the meropenem group and 17.8 (+/- 6.8) in the imipenem/cilastatin group. The primary infections were nosocomial lower respiratory tract infections (56% of patients), intra-abdominal infections (15%), septicaemia (21%), skin/skin structure infections (5%), and complicated urinary tract infections (3%); 35% of the patients had two or more infections. There was no significant difference between the meropenem and imipenem/cilastatin groups in the rates of satisfactory clinical (weighted percentage 87% vs. 74%) or bacteriological (weighted percentage 79% vs. 71%) response. There was a slightly higher rate of clinical success with meropenem against primary or secondary lower respiratory tract infection (89% vs. 76%). Drug-related adverse events occurred in 17% and 15% of meropenem and imipenem/cilastatin patients, respectively. Meropenem (1 g t.i.d.) was as efficacious as the same dose of imipenem/cilastatin in this setting, and both drugs were well tolerated.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/BF01700407 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Suggested Dosing of Select Beta-lactam Agents for the Treatment of Antimicrobial-Resistant Gram-Negative Infections in Children.
J Pediatric Infect Dis Soc
January 2025
Department of Pediatrics, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Background: The Infectious Diseases Society of America (IDSA) publishes annual guidance on the treatment of antimicrobial-resistant (AMR) gram-negative infections. Within the AMR guidance, suggested dosages of antibiotics for adults infected with AMR pathogens are provided. This document serves as a companion document to the IDSA guidance to assist pediatric specialists with dosing β-lactam agents for the treatment of AMR infections in children.
View Article and Find Full Text PDFFirst case report of a vertebral osteomyelitis caused by carbapenem-resistant treated with imipenem/cilastatin/relebactam prolonged infusion then meropenem/vaborbactam in continuous infusion.
Front Pharmacol
October 2024
Department of Infectious and Tropical Diseases, Nimes University Hospital, Nîmes, France.
Article Synopsis
- Bone and joint infections (BJIs) from multidrug-resistant bacteria, like carbapenem-resistant Enterobacterales, are rising, highlighting the need for new treatment options.
- Novel β-lactam/β-lactamase inhibitors, specifically imipenem/cilastatin/relebactam (I-R) and meropenem/vaborbactam (MVB), lack sufficient data on their effectiveness for BJIs, particularly with prolonged infusions.
- A case study showed successful treatment of vertebral osteomyelitis using extended and continuous infusions of I-R and MVB, suggesting these methods could be effective against BJIs caused by resistant bacteria.
In vivo development of resistance to novel β-lactam/β-lactamase inhibitor combinations in KPC-producing Klebsiella pneumoniae infections: a case series.
Eur J Clin Microbiol Infect Dis
December 2024
Microbiology and Virology Unit, Azienda Ospedaliera Universitaria Integrata Di Verona, Verona, Italy.
Article Synopsis
- The study investigates how KPC variants of Klebsiella pneumoniae develop resistance to new β-lactam/β-lactamase inhibitor combinations (βL/βLICs) among patients treated with these antibiotics.
- Researchers conducted a case series involving four patients with bloodstream infections linked to KPC-Kp, noting that most had underlying health issues and experienced severe complications.
- Resistance mutations were identified in the KPC genes following treatment, emphasizing that the use of novel βL/βLICs can lead to the emergence of resistant strains, particularly against ceftazidime/avibactam.
Recent updates in treating carbapenem-resistant infections in patients with hematological malignancies.
Expert Rev Anti Infect Ther
December 2024
Faculty of Medicine, Infectious Diseases and Clinical Microbiology, Hacettepe University, Ankara, Türkiye.
Article Synopsis
- * The optimal treatment for certain resistant infections is ceftazidime/avibactam, with other alternatives like imipenem/cilastatin/relebactam and meropenem/vaborbactam serving as backup options, especially for KPC-positive cases.
- * Emerging treatment strategies involve using combinations such as ceftazidime/avibactam with aztreonam for tougher infections, while AI-driven risk models can help predict infection risks in vulnerable patients.
Tumor complete response and pyogenic liver abscess secondary to concurrent microwave ablation plus atezolizumab and bevacizumab in liver cancer: a case report.
J Gastrointest Oncol
August 2024
Department of Interventional Radiology, Jilin Cancer Hospital, Changchun, China.
Article Synopsis
- * After experiencing symptoms like fever and chills, imaging revealed a large abscess in the liver, leading to a diagnosis of PLA complicated by septic shock, for which the patient underwent extensive antibiotic treatment and drainage procedures over 90 days.
- * Despite initial complications, the patient later returned to treatment and eventually achieved a complete response to the cancer therapies, highlighting the need to weigh the risks of PLA against the benefits of these cancer treatments.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!